Clearside Biomedical (CLSD) Tops Q4 EPS by 1c

Clearside Biomedical (NASDAQ: CLSD) reported Q4 EPS of ($0.08), $0.01 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $6.34 million versus the consensus estimate of $4.43 million.

For earnings history and earnings-related data on Clearside Biomedical (CLSD) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Kodiak Sciences Inc. (KOD) Misses Q2 EPS by 7c
• Innovaro (INV) Misses Q2 EPS by 9c